February 26, 2017 6:00 PM ET

Biotechnology

Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs). The company’s advanced TPTs are in clinical development for cancers, which have significant unmet needs for patients. It is developing Vicinium that is in active Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for late stage squamous cell carcinoma of the head and neck, preparing for a Phase 2 clinical trial in combination with cancer immunotherapy. The company was founded i...

245 First Street

Suite 1800

Cambridge, MA 02142

United States

Founded in 2008

36 Employees

Phone:

617-444-8550

Key Executives for Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics, Inc. does not have any Key Executives recorded.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 08:30 AM

Eleven Biotherapeutics, Inc. Presents at 19th Annual BIO CEO & Investor Conference, Feb-14-2017 08:30 AM. Venue: The Waldorf Astoria New York, 301 Park Avenue, New York, NY 10022, United States. Speakers: Stephen A. Hurly, Chief Executive Officer, President and Director.

Eleven Biotherapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Eleven Biotherapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Eleven Biotherapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016

Eleven Biotherapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported total revenue of $28,651,000 compared to $67,000 a year ago. The increase was due to the revenue recognized from the License Agreement with Roche. Profit from operations was $19,530,000 compared to loss of $9,359,000 a year ago. Net profit was $19,487,000 or $0.91 per basic and diluted share compared to loss of $9,693,000 or $0.50 per basic and diluted share a year ago. The change was primarily the result of the revenue recognized from the License Agreement with Roche. For the nine months, the company reported total revenue of $29,156,000 compared to $425,000 a year ago. Profit from operations was $6,488,000 compared to loss of $25,358,000 a year ago. Net profit was $5,422,000 or $0.26 per basic and diluted share compared to loss of $23,123,000 or $1.23 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 21, 2016
Viventia Bio Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eleven Biotherapeutics, Inc., please visit www.elevenbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.